Docking and PLS Studies on a Set of Thiophenes RNA Polymerase Inhibitors Against Staphylococcus aureus

Current Topics in Medicinal Chemistry

Volumn 14, Issue 1, 2014, Pages 64-80

  Scotti, Luciana ^a   Lima, Edeltrudes de Oliveira ^a   da Silva, Marcelo Sobral ^a   Ishiki, Hamilton ^b   Lima, Igara de Oliveira ^c   Pereira, Fillipe de Oliveira ^c   Mendonça Junior, Francisco Jaime Bezerra ^d   Scotti, Marcus Tullius ^a  

^a FEDERAL UNIVERSITY OF PARAÍBA   (Brazil)

^b University of Oeste Paulista   (Brazil)

^c FEDERAL UNIVERSITY OF CAMPINA GRANDE   (Brazil)

^d STATE UNIVERSITY OF PARAÍBA   (Brazil)

Author keywords

Docking; PLS; QSAR; RNA polymerase; Staphylococcus aureus; Tiophene

Indexed keywords

RIFAMPICIN; RNA POLYMERASE; THIOPHENE;

ARTICLE; BINDING AFFINITY; COMPUTER SIMULATION; DRUG SYNTHESIS; ENZYME ACTIVE SITE; HYDROGEN BOND; HYDROPHOBICITY; IC 50; MOLECULAR DOCKING; MOLECULAR INTERACTION; MOLECULAR MODEL; NONHUMAN; PARTIAL LEAST SQUARES REGRESSION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DNA-DIRECTED RNA POLYMERASES; ENZYME INHIBITORS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SOFTWARE; STAPHYLOCOCCUS AUREUS; STRUCTURAL HOMOLOGY, PROTEIN; THIOPHENES;

EID: 84891817908     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026613666131113151347     Document Type: Article

References (96)

1. Peres, A.G.; Madrenas, J. The broad landscape of immune interactions with Staphylococcus aureus: From commensalism to lethal infections. Burns, 2013, 39 (3), 380-388.
2. Garcia, L.G.; Lemaire, S.; Kahl, B.C.; Becker, K.; Proctor, R.A.; Denis, O.; Tulkens, P.M.; Bamkeke, F.V. Antibiotic activity against small-colony variants of Staphylococcus aureus: review of in vitro, animal and clinical data. J. Antimicrob. Chemother., 2013; 68, 1455-1464.
3. Carrier, M; Marchand, R.; Auger, P.; Hébert, Y.; Pellerin, M.; Bouchard, D.; Poirer, N.; Pagé, P. Methicillin-resistant Staphylococcus aureus infection in a cardiac surgical unit. J. Thorac. Cardiovascular Surg., 2002, 123 (1), 40-44.
4. Barry, C.E. Lessons from Seven Decades of Antituberculosis Drug Discovery. Curr. Top. Med. Chem., 2011, 11, 1216-1225.
5. Schweizer, M.L.; Bossen, A.; McDaniel, J.S. Staphylococcus aureus Colonization before Infection Is Not Associated with Mortality among S. aureus-Infected Patients: A Meta-analysis. Infect. Control Hosp. Epidemiol., 2012, 33 (8), 796-802.
6. Kang, C-I.; Song, J-H.; Ko, K.S.; Peck, K.R. Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study Group. Clinical significance of Staphylococcus aureus infection in patients with chronic liver diseases. Liver Int., 2010, 30 (9), 1333-1338.
7. Honda, H.; Krauss, M.J.; Jones, J.C.; Olsen, M.A. The Value of Infectious Diseases Consultation in Staphylococcus aureus Bacteremia. Am. J. Med., 2010, 123 (7), 631-637.
8. Rao, L.; Karls, R.K.; Betley, M.J. Transcription of Pathogenesis-Related Genes by Purified RNA Polymerase from Staphylococcus aureus. J. Bacteriol., 1995, 177, 2609-2614.
9. Kim, J.; Joo, E-J.; Ha, Y.E.; Park, S.Y.; Kang, C-I.; Chung, D.R.; Song, J.-H.; Peck, K.R. Impact of a computerized alert system for bacteremia notification on the appropriate antibiotic treatment of Staphylococcus aureus bloodstream infections. Eur. J. Clin. Microbiol. Infect. Dis., 2013, 32, 937-945.
10. N'Guyen, Y.; Baumard, S.; Vernet-Garnier, V.; Batalla, A.S.; Champs, C.D.; Jaussauud, R.; Strady, C. Coagulase-negative Staphylococcus bacteraemia accounts for one third of Staphylococcus bacteraemia in a French university hospital. Scand. J. Infect. Dis., 2012, 44, 79-85.
11. Baltz, R.H. Molecular engineering approaches to peptide, polyketide and other antibiotics. Nature Biotech., 2006, 24 (12), 1533-1540.
12. Balciunas, E.M.; Martinez, F.A.C.; Todorov, S.D.; Franco, B.D.G.M.; Converti, A.; Oliveira, R. PP.S. Novel biotechnological applications of bacteriocins: A review. Food Control, 2013, 32, 134-142.
13. Szalewska-Paasz, A.; Wegrzyn, G.; Wegrzyn, A. Mechanisms of physiological regulation of RNA synthesis in bacteria: new discoveries breaking old schemes. J. Appl. Genet., 2007, 48, 281-294.
14. Vandecasteele, S.J.; Peetermans, W.E.; Merckx, R.; Ranst, M.V.; Eldere, J.V. Use of gDNA as Internal Standard for Gene Expression in Staphylococci in vitro and in vivo. Biochem. Biophys. Res. Commun., 2002, 291, 528-534.
15. Osmundson, J.; Montero-Diez, C.; Westblade, L.F.; Hochschild, A.; Darst, S.A. Promoter-Specific Transcription Inhibition in Staphylococcus aureus by a Phage Protein. Cell, 2012, 151, 1005-1016.
16. Pullen, J.; Stolk, L.M.L.; Degrauewe, P.L.J.; Tiel, F.H.V.; Neef, C.; Zimmermann, L.J.I. Pharmacokinetics of Intravenous Rifampicin (Rifampin) in Neonates. Ther. Drug. Monit. 2006, 28, 654-661.
17. Rodgers, W.; Frazier, A.D.; Champney, W.S. Solithromycin Inhibition of Protein ynthesis and Ribosome Biogenesis in Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenza. Antimicrob. Agents Chemother., 2013, 57, 1632-1637.
18. Jeong, Y-C.; Anwar, M.; Bikadi, Z.; Hazai, E. Natural product inspired antibacterial tetramic acid libraries with dual enzyme inhibition. Chem. Sci., 2013, 4, 1008-1015.
19. O'Neill, A.J.; Huovinen, T.; Fishwick, C.W.G.; Chopra, I. Molecular Genetic and Structural Modeling Studies of Staphylococcus aureus RNA Polymerase and the Fitness of Rifampin Resistance Genotypes in Relation to Clinical Prevalence. Antimicrob. Agents Chemother., 2006, 50, 298-309.
20. Coiffier, G.; Albert, J-D.; Arvieux, C.; Guggenbuhl, P. Optimizing combination rifampin therapy for staphylococcal osteoarticular infections. Joint Bone Spine, 2013, 80, 11-17.
21. Jr, G.W.S.; Deng, Y.; Wang, T.; Popovici-Muller, J.; Curran, P.J.; Rosner, K.E.; Cooper, A.B.; Girijavallabhan, V.; Butkiewicz, N.; Cable, M. Aminothiazole inhibitors of HCV RNA polymerase. Bioorg. Med. Chem. Lett., 2005, 15, 115-119.
22. Parrish, J.P.; Lee, S.K.; Boojamra, C.G.; Hui, H.; Babusis, D.; Brown, B.; Shih, I-H.; Feng, J.Y.; Ray, A.S.; Mackman, R.L. Evaluation of 2'-E-fluorine modified nucleoside phosphonates as potential inhibitors of HCV polymerase. Bioorg. Med. Chem. Lett., 2013, 23, 3354-3357.
23. Rand, K.H.; Houck, H.J.; Silverman, J.A. Daptomycin-reversible rifampicin resistance in vancomycin-resistant Enterococcus faecium J. Antimicrob. Chemother. 2007, 59, 1017-1020.
24. Knegt, G.J.; Bruning, O.; Kate, M.T.T.; Jong, M.; Belkum, A.V.; Endtz, H.P.; Breit, T.M.; Bakker-Woundenberg, I.A.J.M.; Steenwinkel, J.E.M. Rifampicin-induced transcriptome response in rifampicin-resistant Mycobacterium tuberculosis. Tuberculosis. 2013, 93, 96-101.
25. Arhin, A.; Bélanger, O.; Ciblat, S.; Dehbi, M.; Delorme, D.; Dietrich, E.; Dixit, D.; Lafontaine, Y.; Lehoux, D.; Liu, J.; McKay, G.A.; Moeck, G.; Reddy, R.; Rose, Y.; Srikumar, R.; Tanaka, K.S.E.; Williams, D.M.; Gros, P.; Pelletier, J.; Jr, T.R.P.; Far, A.R. A new class of small molecule RNA polymerase inhibitors with activity against Rifampicin-resistant Staphylococcus aureus. Bioorg. Med. Chem., 2006, 14, 5812-5832.
26. Campaigne, E.; Weinberg, E.D.; Carlson, G.; Neiss, E.S. Benzo[β]thiophene Derivatives. V. Mannich Bases with Antimicrobial Activity. J. Med. Chem., 1965, 8 (1), 136-137.
27. Dzhuraev, A.D.; Karimkulov, K.M.; Makhsumov, A.G.; Amanov, N. Antimicrobial activity of novel thiophene derivatives. Pharm. Chem. J., 1992, 26, 882-884.
28. El-Maghraby, A.A.; Mohamed, N.A. Synthesis of some new thiophene derivatives with antimicrobial activity. part I. J. Chem. Tech. Biotech., 1983, 33 (1), 25-32.
29. Khalil, A.M.; Berghot, M.A.; El-Ghani, G.E.A.; Gouda, M.A. Synthesis and Antimicrobial Evaluation of Some New Thiophene Derivatives. Synth. Commun.: Int. J. Rapid Commun. Synth. Org. Chem., 2010, 40 (11), 1658-1669.
30. Gouda, M.A.; Berghot, M.A.; El-Ghani, G.E.A.; Khalil, A.M. Synthesis and antimicrobial activities of some new thiazole and pyrazole derivatives based on 4, 5, 6, 7-tetrahydrobenzothiophene moiety. Eur. J. Med. Chem., 2010, 45 (4), 1338-1345.
31. Isloor, A.M.; Kalluraya, B.; Pai, K.S. Synthesis, characterization and biological activities of some new benzo[β]thiophene derivatives. Eur. J. Med. Chem., 2010, 45 (2), 825-830.
32. Mishra, R.; Tomer, I.; Kumar, S. Synthesis and antimicrobial evaluation of novel thiophene derivatives. Der Pharm. Sinica, 2012, 3 (3), 332-336.
33. Bondock, S.; Fadaly, W.; Metwally, M.A. Synthesis and antimicrobial activity of some new thiazole, thiophene and pyrazole derivatives containing benzothiazole moiety. Eur. J. Med. Chem., 2010, 45, 3692-3701.
34. Masunari, A.; Tavares, L.C. A new class of nifuroxazide analogues: Synthesis of 5-nitrothiophene derivatives with antimicrobial activity against multidrug-resistant Staphylococcus aureus. Bioorg. Med. Chem., 2007, 15 (12), 4229-4236.
35. Chabert, J.F.; Marquez, B.; Neville, L.; Joucla, L.; Broussous, S.; Bouhours, P.; David, E.; Pellet-Rostaing, S.; Marquet, B.; Moreau, N.; Lemaire, M. Synthesis and evaluation of new arylbenzo[β]thiophene and diarylthiophene derivatives as inhibitors of the NorA multidrug transporter of Staphylococcus aureus. Bioorg. Med. Chem., 2007, 15 (13), 4482-4497.
36. Hou, T.; Wang, J.; Li, Y.; Wang, W. Assessing the performance of the molecular mechanics/Poisson Boltzmann surface area and molecular mechanics/generalized Born surface area methods II: The accuracy of ranking poses generated from docking. J. Comput. Chem., 2011, 32 (5), 866-877.
37. Okimoto, N.; Futatsugi, N.; Fuji, H.; Suenaga, A.; Morimoto, G.; Yanai, R.; Ohno, Y.; Narumi, T.; Taiji, M. High-performance drug discovery: computational screening by combining docking and molecular dynamics simulations. PLoS Comput. Biol., 2009, 5 (10), e1000528.
38. Scotti, L.; Ishiki, H.M.; Ferreira, M.J.P.; Júnior, F.J.B.M.; Emerenciano, V.P.; Da Silva, M.S.; Scotti, M.T.; In Silico Methods Applied In Food Chemistry: A Short Review With Bitter And Mutagenic Compounds. Lett. Drug Des. Dis., 2012, 9, 527-534.
39. Cramer, P.; Armache, K.-J.; Baumli, S.; Benkert, S.; Brueckner, F.; Buchen, C.; Damsma, G.E.; Dengl, S.; Geiger, S.R.; Jasiak, A.J.; Jawhari, A.; Jennebach, S.; Kamenski, T.; Kettenberger, H.; Kuhn, C.-D.; Lehmann, E.; Leike, K.; Sydow, J.F.; Vanini, A. Structure of Eukaryotic RNA Polymerases. Annu. Rev. Biophys., 2008, 37, 337-352.
40. Devaiah, B.N.; Singer, D.S. Cross-talk Among RNA Polymerase II Kinases Modulates C-terminal Domain Phosphorylation. J. Biol. Chem., 2012, 287 (46) 38755-38766.
41. Chambers, R.S.; Wang, B.Q.; Burton, Z.F.; Dahmus, M.E. The Activity of COOH-terminal Domain Phosphatase Is Regulated by a Docking Site on RNA Polymerase II and by the General Transcription Factors IIF and IIB. J. Biol. Chem., 1995, 270, 14962-14969.
42. Cramer, P.; Bushnell, D.A.; Komberg, R.D. Structural basis of transcription: RNA polymerase II at 2. 8 angstrom resolution. Science, 2001, 8, 1863-1876.
43. Tellez, A.B.; Crowder, S.; Spagnolo, J.F.; Thompson, A.A.; Peersen, O.B.; Brutlag, D.G.; Kirkegaard, K. Nucleotide Channel of RNA-dependent RNA Polymerase used for Intermolecular Uridylylation of Protein Primer. J. Mol. Biol., 2006, 357, 665-675.
44. Josa, D.; da Cunha, E.F.; Ramalho, T.C.; Souza, T.C.; Caetano, M.S. Homology modeling of wild-type, D516V, and H526L Mycobacterium tuberculosis RNA polymerase and their molecular docking study with inhibitors. J. Biomol. Struct. Dyn., 2008, 25 (4), 373-376.
45. Rossini, M.; Scotti, M.T.; Correia, M.V.; Fokoue, H.H.; Scotti, L.; Júnior, F.J.B.M.; Da Silva, M.S.; Emerenciano, V.P. Sesquiterpene Lactones with Anti-Hepatitis C Virus Activity Using Molecular Descriptors. Lett. Drug Des. Dis., 2012, 9, 881-890.
46. 13C NMR Spectral Data And Molecular Descriptors To Predict The Antioxidant Activity Of Flavonoids. Braz. J. Pharm. Sci., 2011, 47, 241-249.
47. Scotti, L.; Scotti, M.T.; Ishiki, H.M.; Ferreira, M.J.P.; Emerenciano, V.P.; Menezes, C.M.S.; Ferreira, E.I. Quantitative elucidation of the structure-bitterness relationship of cynaropicrin and grosheimin derivatives. Food Chem., 2007, 105, 77-83.
48. Scotti, L.; Moreira, D.; Da Silva, M.S.; Pitta, I.R.; Scotti, M.T. SAR, QSAR and Docking of Anticancer Flavonoids and Variants: A Review. Curr. Top. Med. Chem., 2012, 12, 2785-2809.
49. Sahu, V.; Sharma, P.; Kumar, A. Synthesis and QSAR modeling 1-3-methyl-2-(aryldiazenyl)-2H-aziren-2-yl ethanones as potential antibacterial agents. Med. Chem. Res., 2013, 22 (5), 2476-2485.
50. Ozbek, N.; Alyar, S.; Alyar, H.; Sahin, E.; Karacan, N. Synthesis, characterization and anti-microbial evaluation of Cu (II), Ni (II), Pt (II) and Pd (II) sulfonylhydrazone complexes; 2D-QSAR analysis of Ni (II) complexes of sulfonylhydrazone derivatives. Spectrochim. Acta Part a-Mol. Biomol. Spectros., 2013, 108, 123-132.
51. Mor, S.; Pahal, P.; Narasimhan, B. Synthesis, characterization, antimicrobial activities and QSAR studies of some 10aphenylbenzo β indeno 1, 2-e 1, 4 thiazin-11 (10aH)-ones. Eur. J. Med. Chem., 2012, 53, 176-189.
52. Singh, M.; Kumar, S.; Kumar, A.; Kumar, P.; Narasimhan, B. Synthesis, antimicrobial evaluation, and QSAR analysis of 2-isopropyl-5-methylcyclohexanol derivatives. Med. Chem. Res., 2012, 21 (4), 511-522.
53. Umamatheswari, S.; Balaji, B.; Ramanathan, M.; Kabilan, S. Synthesis, stereochemistry, antimicrobial evaluation and QSAR studies of 2, 6-diaryltetrahydropyran-4-one thiosemicarbazones. Eur. J. Med. Chem., 2011, 46 (4), 1415-1424.
54. Khalafi-Nezhad, A.; Rad, M.N.S.; Mohabatkar, H.; Asrari, Z.; Hemmateenejad, B. Design, synthesis, antibacterial and QSAR studies of benzimidazole and imidazole chloroaryloxyalkyl derivatives. Bioorg. Med. Chem., 2005, 13 (6), 1931-1938.
55. Narasimhan, B.; Judge, V.; Narang, R.; Ohlan, R.; Ohlan, S. Quantitative structure-activity relationship studies for prediction of antimicrobial activity of synthesized 2, 4-hexadienoic a id derivatives. Bioorg. Med. Chem. Lett., 2007, 17 (21), 5836-5845.
56. Karki, R.G.; Kulkarni, V.M. Three-dimensional quantitative structure-activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials. Bioorg. Med. Chem., 2001, 9 (12), 3153-3160.
57. Sabet, R.; Fassihi, A.; Hemmateenejad, B.; Saghaei, L.; Miri, R.; Gholami, M. Computer-aided design of novel antibacterial 3-hydroxypyridine-4-ones: application of QSAR methods based on the MOLMAP approach. J. Comp. Aided Mol. Des., 2012, 26 (3), 349-361.
58. Cherkasov, A.; Hilpert, K.; Jenssen, H.; Fjell, C.D.; Waldbrook, M.; Mullaly, S.C.; Volkmer, R.; Hancock, R.E.W. Use of Artificial Intelligence in the Design of Small Peptide Antibiotics Effective against a Broad Spectrum of Highly Antibiotic-Resistant Superbugs. Acs Chem. Biol., 2009, 4 (1), 65-74.
59. Marrero-Ponce, Y.; Medina-Marrero, R.; Torrens, F.; Martinez, Y.; Romero-Zaldivar, V.; Castro, E.A. Atom, atom-type, and total nonstochastic and stochastic quadratic fingerprints: a promising approach for modeling of antibacterial activity. Bioorg. Med. Chem., 2005, 13 (8), 2881-2899.
60. Nanda, A.K.; Ganguli, S.; Chakraborty, R. Antibacterial activity of some 3-(Arylideneamino)-2-phenylquinazoline-4 (3H)-ones: Synthesis and preliminary QSAR studies. Molecules, 2007, 12 (10), 2413-242.
61. HyperChem, Version 8. 0; Hybercube Inc.: Gainesville, FL, USA, 2009.
62. Allinger, N.L. A hydrocarbon force-field utilizing V1 and V2 torsional terms. J. Am. Chem. Soc. 1977, 99, 8127-8134.
63. Dewar, M.J.S.E.; Zoebisch, G.; Healy, E.F.; Stewart J.J.P. AM1: A new general purpose quantum mechanical molecular model. J. Am. Chem. Soc. 1985, 107, 3902-3909.
64. Cohen, N.C. Guidebook on Molecular Modeling in Drug Design; Academic Press: San Diego, CA, USA, 1996.
65. Leach, A.R. Molecular Modeling: Principles and Applications; Prentice Hall: London, UK, 2001.
66. Spartan model homepage for windows, available at http: //www. wavefun. com/products/windows/SpartanModel/win_m odel. html, access in April 2013.
67. Duran, A.; Zamora, I; Pastor, M. Suitability of GRIND-Based Principal Properties for the Description of Molecular Similarity and Ligand-Based Virtual Screening. J. Chem. Inf. Model., 2009, 49, 2129-2138.
68. Alcaide, Á.D. Doctoral Thesis, Universitat Pompeu Fabra, 2009.
69. Fontaine, F.; Pastor, M.; Sanz F. Incorporating Molecular Shape into the Alignment-free GRid-Independent Descriptors, J. Med. Chem., 2004, 47, 2805-2815.
70. Pastor, M.; Mclay, I.; Pickett, S.; Clementi, S. Grid-Independent descriptors (GRIND): A novel class of alignment-independent three-dimensional molecular descriptors. Med. Chem. 2000, 43, 3233-3243.
71. Ermondi, G.; Caron, G. GRIND-based 3D-QSAR to predict inhibitory activity for similar enzymes, OSC and SHC, Eur. J. Med. Chem., 2008, 43, 1462-1468.
72. Dúran, A.; Martínez, G.; Pastor, M. Development and Validation of AMANDA, a New Algorithm for Selecting Highly Relevant Regions in Molecular Interaction Fields, J. Chem. Inf. Model., 2008, 48, 1813-1823.
73. Zamora, I.; Oprea, T.; Cruciani, G.; Pastor, M.; Ungell, A.-L. Surface descriptors for protein-ligand affinity prediction. J. Med. Chem. 2003, 46, 25-33.
74. Goodford, P.J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem., 1985, 28, 849-857.
75. Golbraikh, A.; Shen, M.; Xiao, Z.; Xiao, Y-D.; Lee, K-H.; Tropsha, A. Rational selection of training and test sets for the development of validated QSAR models. J. Comput. Aided Mol Des., 2003, 17, 241-253.
76. The UniProt Consortium, Update on activities at the Universal Protein Resource. Nucleic Acids Res., 2013, 41, D43-D47.
77. Holden, M.T.G.; Feil, E.J.; Lindsay, J.A.; Peacock, S.J.; Day, N.P.J.; Enright, M.C.; Foster, T.J.; Moore, C.E.; Hurst, L.; Atkin, R.; Barron, A.; Bason, N.; Bentley, S.D.; Chillingworth, C.; Chillingworth, T.; Churcher, C.; Clark, L.; Corton, C.; Parkhill, J. Complete genomes of two clinical Staphylococcus aureus strains: evidence for the rapid evolution of virulence and drug resistance. J. Proc. Natl. Acad. Sci. U.S.A., 2004, 101, 9786-9791.
78. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The protein data bank. Nucleic Acids Res., 2000, 28 (1), 235-242.
79. Molodtsov, V.; Nawarathne, I.N.; Scharf, N.T.; Kirchhoff, P.D.; Showalter, H.D.; Garcia, G.A.; Murakami, K.S. X-ray Crystal Structures of the Escherichia coli RNA Polymerase in Complex with Benzoxazinorifamycins. J. Med. Chem., 2013, 56, 4758-4763.
80. Vassylyev, D.G.; Svetlov, V.; Vassylyeva, M.N.; Perederina, A.; Igarashi, N.; Matsugaki, N.; Wakatsuki, S.; Artsimovitch, I. Structural basis for transcription inhibition by tagetitoxin. Nat. Struct. Mol. Biol., 2005, 12, 1086-1093.
81. Huang, X.; Miller, W. A time-efficient, linear-space local similarity algorithm. Adv. Appl. Math., 1991, 12, 337-357.
82. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity. J. Comput. Chem., 2009, 16, 2785-2791.
83. Pedretti, A.; Villa, L.; Vistoli, G. VEGA-an open platform to develop chemo-bio-informatics applications, using plug-in architecture and script programming, J.C.A.M.D., 2004, 18, 167-173.
84. Molegro, available at http: //www. clcbio. com/products/molegro/ #molecular-viewer access in August, 2013.
85. Wolf, L.K. New software and Websites for the Chemical Enterprise, Chem. Eng. News, 2009, 87, 31.
86. Hekkelman, M.L.; Beek, T.A.H.; Pettifer, S.R.; Thorne, D.; Attwood, T.K.; Vriend, G. WIWS: a protein structure bioinformatics Web service collection. Nucleic Acids Res., 2010, 38, W719-W723.
87. Cruciani, G.; Pastor, M.; Guba, W. VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. Eur. J. Pharm. Sci., 2000, 11 (Suppl. 2) (2000) S29-39.
88. Aligiannis, N.; Kalpoutzakis, E.; Mitaku, S.; Chinou, I.B., Composition and antimicrobial activity of the essential oils of two Origanum species. J. Agr. Food Chem., 2001, 49 (9), 4168-4170.
89. Houghton, P.J.; Howes, M.J.; Lee, C.C.; Steventon, G., Uses and abuses of in vitro tests in ethnopharmacology: Visualizing an elephant. J. Ethnopharmacol., 2007, 110 (3), 391-400.
90. Holetz, F.B.; Howes, M.J.; Lee, C.C.; Steventon, G. Screening of some plants used in the Brazilian folk medicine for the treatment of infectious diseases. Mem. I. Oswaldo Cruz, 2002, 97 (7), 1027-1031.
91. Mendonca Junior, F.J.B.; De Lima-Neto, R.G.; De Oliveira, T.B.; Lima, M.C.A.; Pitta, I.R.; Galdino, S.L.; Da Cruz, R.M.D.; De Araujo, R.S.A.; Neves, R.P. Synthesis and Evaluation of the Antifungal Activity of 2-(Substituted-Amino)-4, 5-Dialkyl-Thiophene-3-Carbonitrile Derivatives. Acta Farmacéut. Bonaerense, 2011, 30, 1492-1499.
92. Souza, B.C.C.; De Oliveira, T.B.; Aquino, T.M.; de Lima, M.C.A.; Pitta, I.R.; Galdino, S.L.; Lima, E.O.; Goncalves-Silva, T.; Militao, G.C.G.; Scotti, L.; Scotti, M.T.; Mendonca, F.J.B. Preliminary antifungal and cytotoxic evaluation of synthetic cycloalkyl b thiophene derivatives with PLS-DA analysis. Acta Pharm., 2012, 62 (2), 221-236.
93. Fortes, A.C.; Almeida, A.A.C.; Mendonca, F.J.B.; Freitas, R.M.; Soares-Sobrinho, J.L.; Soares, M.F.D., Anxiolytic Properties of New Chemical Entity, 5TIO1. Neurochem. Res., 2013, 38 (4), 726-731.
94. Ribeiro, F.F.; Síntese, Caracterização e Avaliação da Citotoxicidade frente à Artemia salina de novos derivados sintéticos 2-[(benzilideno) amino]-4, 5, 6, 7-tetraidro-4h-benzo[b]tiofeno-3-carbonitrila. Monograph of the Biological Sciences course-Universidade Estadual da Paraíba, Campina Grande, December 2011.
95. De Oliveira, J.G.B.; Síntese, Purificação, Caracterização Estrutural e Avaliação Da Citotoxicidade de Novos Derivados 2-amino-5, 6-diidro-4h-ciclopenta[b]tiofeno-3-carbonitrila em bioensaios de Artemia salina. Monograph of the Biological Sciences course-Universidade Estadual da Paraíba, João Pessoa, December 2011.
96. Dong, D.; Wu, B. In Silico Modeling of UDP-Glucuronosyltransferase 1A10 Substrates Using the VolSurf Approach. J. Pharm. Sci., 2012, 101 (9), 3531-3539.